[ Inside the business ]
ANIP stock analysis
ANIP · Ani Pharmaceuticals Inc
Pharmaceutical preparations. Growing 28%.
Nothing unusual in its latest filings.
The future, in 7 questions
Needs today's sales, share count and price.
✓ All clear
From SEC filings, price and Radar. Not advice.
The record
Early signals
Growth speeding up.
Sales growth +20%, +26%, then +28% vs. a year ago.
Early signals
Growth speeding up.
Sales growth vs. a year ago, by quarter ending
What just happened
Signals in the filings
Early signals· full write-up
Growth speeding up.
Early signals Improving
What's changing in the filings before it shows up in yearly results. Signals, not predictions.
New since last 10-Q (Nov 5, 2026)
Nov 16, 2026 · Investor disclosure. The Company may use the updated investor presentation in various meetings with investors and analysts from time to time. From 8-KGrowth momentum: sales vs. a year ago, by quarter Calculated
Signals in the filings
What could go wrong
Few warning signs.
It has moved 0.8× the market. In the 2008 crisis it fell 77% while the market fell 51%. Debt is covered by cash.
What could go wrong
Few warning signs.
Red-flag scan, last 3 years
Past shocks replayed stock S&P 500
Cash vs. debt
What could go wrong· full write-up
Few warning signs.
8 · What could go wrong
Warning signs in the filings, debt, how it reacts to the economy, and the risks it names
Red-flag scan, last 3 years
Modeled on the SEC's published Accounting Quality Model description, not SEC scores
Debt and leverage as of Sep 30, 2026
Macro risk 118 months to Oct 2026 Calculated
Stress test: past shocks replayed stock vs. S&P 500, month-end prices
Right now: last 3 months Reported
What if the market falls?
Historically, about -16% for this stock
Based on its 0.81× pattern. Real moves vary a lot, as the stress test shows.
Biggest risks it names
- Our net revenues were concentrated among three customers, which represented 22%, 17%, and 14% of our net revenues during the year ended December 31, 2025. From 10-K
Full list: risk factors in the 10-K (Item 1A)
Speculative check
Not classified.
Not Self-funding because of: issuing 5%+ new shares a year.
Speculative check
Not classified.
Not Self-funding because of: issuing 5%+ new shares a year. Price is 1.4× yearly revenue.
Speculative check· full write-up
Not classified.
Speculative check: does the business pay for itself?
Self-funding: every condition true, across all three statements. Income statement: revenue of $100M or more, a gross profit, an operating profit, a net profit (last 12 months) and a profit in the latest quarter. Balance sheet: current ratio of 1 or more, positive equity, debt manageable (cash at least the debt, or debt no more than 4 years of operating profit before depreciation). Cash flow: positive cash from operations and positive free cash flow. Plus: new shares under 5% a year, no going-concern warning, Altman Z-score out of the distress zone and a Piotroski F-score of 4 or more. Companies with both profits and positive operating cash are excused negative equity and a low Altman score (buybacks), a current ratio under 1 and negative free cash flow (heavy investment). Speculative: an operating loss, cash flowing out of operations and under $1B in sales (however much cash it has raised, even if one-off gains made a net profit); or a going-concern warning; or a penny stock (under $5 a share with under $6M revenue). Not classified: everything else, with the reasons listed. Tests that don't apply (like gross margin for banks) are left out. Calculated
Why not Self-funding: issuing 5%+ new shares a year.
Verdict: Not classified, 0 of 13 tests red. Numbers to Sep 30, 2026. Calculated
Net profit: $117M (last 12 months). Is it making money after all costs? Losses aren't bad by themselves, but they mean someone else pays for now. Reported
Operating profit: $166M (last 12 months). Does the business itself make money, before interest, tax and one-off gains? A net profit with an operating loss usually means the profit came from outside the business. Reported
Gross margin: Not available. Does it make money on each sale before overhead? A negative gross margin means every sale loses money. Calculated
Revenue: $1B (last 12 months). Is the business big enough to stand on its own? Under $100 million a year counts as small; under $20 million as tiny. Reported
Cash from operations: $229M (last 12 months). Does the day-to-day business bring cash in, or use it up? Reported
Cash runway: Self-funded (free cash flow $205M a year). If it burns cash, how long until it runs out without raising more money? Cash includes short-term investments; burn is cash from operations minus spending on equipment. Calculated
Debt vs. cash: $298M debt ($421M cash · 1.2× yearly operating profit). Could it pay off its debt? Green when cash covers the debt or debt is under 2 years of operating profit (before depreciation). Reported
Current ratio: 2.7× (short-term assets ÷ bills due within a year). Can it pay the bills due within a year from short-term assets? Below 1× means it can't, without new money. Calculated
Shareholders' equity: $637M (assets exceed debts). Do its assets exceed everything it owes? Negative equity can come from years of losses or from big buybacks, so check which. Reported
New shares issued: +8.0% a year (share count over the last 2 years). Is it selling new shares to survive? Fast-rising share counts shrink each owner's slice. Uses diluted shares from annual reports. Calculated
Going-concern warning: None (in the latest annual report). Auditors must warn when they doubt a company can keep operating for the next year. Any such warning makes the verdict Speculative. From 10-K
Latest quarter profit: $35M (quarter to 2026-09-30). The S&P 500 asks for a profit in the latest quarter as well as over the last four. A loss in the latest quarter can be the first sign of trouble, or a one-off. Reported
Altman Z-score: 2.5 (grey zone). Edward Altman's bankruptcy-risk score from working capital, retained earnings, operating profit, market value and sales. Under 1.8 (1.1 for non-manufacturers) is the distress zone. Reported
Piotroski F-score: 6 of 8 (profit, cash, debt, liquidity, dilution, margins, efficiency vs. last year). Joseph Piotroski's nine pass/fail checks, this year vs. last: profit, operating cash, rising return on assets, cash above profit, less debt, better liquidity, no new shares, better margins, better asset turnover. 0–3 is weak, 7–9 strong. Reported
Benjamin Graham's defensive test (for reference, not part of the verdict): passes 4 of 7. ✓ Sales of $700M or more (his $100M in 1972 money) · ✓ Current ratio of 2 or more · ✓ Long-term debt no more than working capital · ✗ A profit every year (last 10) · ✗ Dividends every year (last 10) · ✓ Earnings up a third or more over the decade (3-year averages) · ✗ Price × earnings × book value moderate (P/E × P/B ≤ 22.5)
Price vs. sales: the market values it at 1.4× its yearly revenue. This is about the stock price, not the business, so it isn't one of the tests. Calculated
A label for learning, not a recommendation. Speculative companies can succeed and self-funding ones can fall.
What they sell
48% Sales of Cortrophin Gel.
Sales of Cortrophin Gel 48% · Sales of Generic Pharmaceutical Products 36% · Sales of ILUVIEN and YUTIQ 8% · Sales of Established Brand Royalties and Other Revenues 4% · other (latest quarter)
What they sell
48% Sales of Cortrophin Gel.
Latest quarter, to Sep 30, 2026
Full year (its older categories)
What they sell· full write-up
48% Sales of Cortrophin Gel.
1 · What they sell fiscal year to Dec 31, 2025
Reported 10-K revenue by product or segment
Latest quarter, to Sep 30, 2026: new categories Reported
Growth vs. the same quarter a year earlier. The company now reports these categories; the yearly split above uses its previous ones.
Rivals it names: The commercialization of new drugs is highly competitive, and the commercial success of our products or any of our future products or product candidates will depend on several factors, including our ability to differentiate any such products or product candidates from our competitors' current or future products,… From 10-K
Where each dollar goes
Not available.
Cost lines aren't reported in a comparable form.
Where each dollar goes
Not available.
Cost lines aren't reported in a comparable form.
Where each dollar goes· full write-up
Not available.
3 · Where each $1 goes last 12 months to Sep 30, 2026
$1.0B revenue Reported
Cost breakdown not available: the filings don't report cost of revenue and operating profit in a comparable form.
Revenue by product fiscal year to Dec 31, 2025
- Sales of Generic Pharmaceutical Products43%
- Sales of Cortrophin Gel39%
- Sales of ILUVIEN and YUTIQ8.5%
- Sales of Established Brands6.9%
- Sales of Royalties and Other Pharmaceutical Services1.7%
Where customers are fiscal year to Dec 31, 2025 Reported
Note: using fiscal year 2025 data. More recent figures not found in the latest quarterly filing.
Its market
1.5× the economy.
The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.
Its market
1.5× the economy.
Output growth a year, 2025–35, after inflation
Its market· full write-up
1.5× the economy.
2 · Where its markets head (10 years)
U.S. industry output growth after inflation, 2025–35
Projected to grow 1.5× as fast as the economy. Jobs in the industry: +0.7% a year. Gov projection
U.S. Bureau of Labor Statistics, Employment Projections 2025–35 (Table 2.11), released Aug 27, 2026
Market size and share
Your call.
There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.
Market size and share
Your call.
4 · Market size and share
Not available: no market size was found in the company's SEC filings. Companies usually give these in investor presentations, which aren't part of their official filings.
Market capture
Needs a market size (above). Nothing is assumed.
Life cycle
Early maturity.
It earns cash, still invests, and pays back more than it borrows. Unusually, sales are still growing like a young company's.
Life cycle
Early maturity.
Life cycle stage Early maturity
Where the company sits, based only on its financials
ANIP, last 12 months to Sep 30, 2026 Reported
Cash pattern (+ − −) = maturity. Sales are still growing like a growth company, so the dot sits just past the line. Inferred
Path over time
Earnings quality
Clean.
Its numbers don't resemble those of past manipulators. Cash covers 196¢ of each $1 of profit.
Earnings quality
Clean.
Beneish M-score: -2.64
Fraud-pattern scores by year · ANIP
| Year | M-score | M zone | F-score | F risk |
|---|---|---|---|---|
| FY20 | −2.47 | 🟢 Clean | 2.16 | 🟠 Above normal |
| FY21 | −2.42 | 🟢 Clean | 1.76 | 🟠 Above normal |
| FY22 | −2.36 | 🟢 Clean | 2.10 | 🟠 Above normal |
| FY23 | −2.96 | 🟢 Clean | 1.13 | 🟠 About normal |
| FY24 | −2.23 | 🟢 Clean | 1.93 | 🟠 Above normal |
| FY25 | −2.64 | 🟢 Clean | 1.43 | 🟠 About normal |
M-score: flagged above −1.78, grey zone −2.22 to −1.78, clean below −2.22. F-score: 1.0 = an average company's risk, above 2.45 = high. Patterns to look into, not proof.
Cash checks
Earnings quality· full write-up
Clean.
5 · Earnings quality
Are the profits backed by cash?
How cautious are you? cost of a miss vs. a false alarm
Not flagged at cutoff -1.28
Vs. 10 peers (Pharmaceutical Preparations): #8 highest · peer median -2.52 · 0 in the high zone Calculated
Fiscal years to Dec 31, 2025 and Dec 31, 2024 · Beneish (1999)
Its fiscal 2025 numbers look 1.4× as much like past SEC fraud cases as an average company's.
Mostly from hard-to-value assets (76% of assets) and money owed by customers (up 4.4% of assets).
| Fiscal year | Beneish M-score | M zone | Dechow F-score | F risk |
|---|---|---|---|---|
| FY2020 | −2.47 | 🟢 Clean | 2.16 | 🟠 Above normal |
| FY2021 | −2.42 | 🟢 Clean | 1.76 | 🟠 Above normal |
| FY2022 | −2.36 | 🟢 Clean | 2.10 | 🟠 Above normal |
| FY2023 | −2.96 | 🟢 Clean | 1.13 | 🟠 About normal |
| FY2024 | −2.23 | 🟢 Clean | 1.93 | 🟠 Above normal |
| FY2025 | −2.64 | 🟢 Clean | 1.43 | 🟠 About normal |
Each year compared with the one before. “Off the scale” usually means a merger, spin-off or restructuring that year. Beneish (1999); Dechow, Ge, Larson & Sloan (2011), model 1.
Competitive advantage
2 of 10 years.
Returns beat its 8.0% cost of capital in 2 of the last 10 years. Gross margin went from 62% to 58%.
Competitive advantage
2 of 10 years.
Return on capital by year, vs. its cost of capital
Competitive advantage· full write-up
2 of 10 years.
6 · Competitive advantage
Can competitors erode its returns? Evidence, not a verdict.
Return on capital by fiscal year; dashed line = 8.0% cost of capital
Source of advantage, per the 10-K: licenses or approvals Inferred · th in the generic pharmaceutical industry has been driven by the increased market acceptance of generic drugs, as well as the number of branded drugs for which patent terms and/or other market exclusivities have expired. From 10-K
Rivals it names: The commercialization of new drugs is highly competitive, and the commercial success of our products or any of our future products or product candidates will depend on several factors, including our ability to differentiate any such products or product candidates from our competitors' current or future products,… From 10-K
Future bets
5% on research.
$51M a year on R&D. $24M on equipment and buildings.
Future bets
5% on research.
Where the money for the years ahead goes
Future bets· full write-up
5% on research.
7 · Future bets
Where is it putting money for the years ahead? Plans and commitments, not outcomes.
All figures from Ani Pharmaceuticals Inc's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.